Artiva Biotherapeutics (ARTV) Share-based Compensation (2023 - 2026)

Artiva Biotherapeutics (ARTV) has reported Share-based Compensation for 4 consecutive years, with $19.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Share-based Compensation rose 4357.01% year-over-year to $19.7 million; the TTM figure through Mar 2026 stood at $19.7 million (up 227.46% YoY), while the FY2025 annual figure was $1.1 million, down 84.24% from the prior year.
• Share-based Compensation improved to $19.7 million in Q1 2026 per ARTV's latest filing, from $7.4 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $19.7 million in Q1 2026 and bottomed at $442000.0 in Q1 2025.
• Historically, Share-based Compensation has averaged $3.9 million across 4 years, with a median of $1.5 million in 2024.
• Annual changes were most pronounced in 2025 — Share-based Compensation plunged 68.56% — and 2026, when it jumped 4357.01%.
• Artiva Biotherapeutics' Share-based Compensation stood at $1.4 million in 2023, then soared by 56.9% to $2.2 million in 2024, then soared by 238.83% to $7.4 million in 2025, then jumped by 166.22% to $19.7 million in 2026.
• Business Quant data shows ARTV's Share-based Compensation at $19.7 million in Q1 2026, $7.4 million in Q3 2025, and $1.5 million in Q2 2025.